The Meropenem Yearly Susceptibility Test Information Collection antimicrobial susceptibility program in Spain:: a 5-year analysis

被引:13
作者
Pascual, Alvaro
Perea, E.
Alvarez, M.
Casal, M.
Garcia de Lomas, J.
Garcia Rodriguez, J. A.
Martin, R.
Soria, G.
Zapardiel, J.
机构
[1] Hosp Virgen Macarena Seville, Seville 41080, Spain
[2] Complejo Hosp Univ Vigo, Vigo 36204, Spain
[3] Hosp Reina Sofia, Cordoba 14004, Spain
[4] Hosp Univ Valencia, Valencia 46010, Spain
[5] Hosp Univ Salamanca, Salamanca, Spain
[6] Salamanca Hosp Univ, Univ Hosp, Barcelona 37007, Spain
[7] Hosp Gen Cataluna, Lab Referencia Catalunya, Barcelona 08195, Spain
[8] AstraZeneca Farmaceut, Madrid 28033, Spain
关键词
MYSTIC program; Meropenem; enterobacteriaceae; Pseudomonas aeruginosa;
D O I
10.1016/j.diagmicrobio.2006.08.013
中图分类号
R51 [传染病];
学科分类号
100401 [流行病与卫生统计学];
摘要
The Meropenem Yearly Susceptibility Test Information Collection program is a global study providing in vitro surveillance data on antimicrobial susceptibility in centers prescribing meropenem. This study summarizes data on the activity of meropenem and 5 comparators against 4022 clinical isolates from 7 centers in Spain (1999-2003). Those bacteria intrinsically resistant to meropenem were excluded. Among Enterobacteriaceae, 100% of Enterobacter spp., Citrobacter spp., and Serratia spp. were susceptible to meropenem. Escherichia coli and Klebsiella pneumoniae susceptibilities to carbapenems were 100% and >= 98%, respectively. Extended-spectrum S-lactamase-producing Enterobacteriaceae were 3.8% of isolates, and all of them were susceptible to meropenem. Ciprofloxacin resistance in E. coli was around 20%. Meropenem and piperacillin/tazobactam were the most active agents against Pseudomonas aeruginosa. Acilletobacter batimannii were 61-90% susceptible to carbapenems, but only 6-21% susceptible to ciprofloxacin. In this period, around 100% of oxacillin-susceptible staphylococci were susceptible to meropenem. There was no significant decrease in susceptibility to the carbapenems throughout the 5-year period. The clinical use of meropenem in 7 Spanish centers did not increase bacterial resistance to this agent in the microorganisms evaluated. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:195 / 200
页数:6
相关论文
共 29 条
[1]
Surveillance of antimicrobial resistance among Gram-negative isolates from intensive care units in eight hospitals in Turkey [J].
Aksaray, S ;
Dokuzoguz, B ;
Güvener, E ;
Yücesoy, M ;
Yulug, N ;
Kocagöz, S ;
Ünal, S ;
Çetin, S ;
Calangu, S ;
Günaydin, M ;
Leblebicioglu, H ;
Esen, S ;
Bayar, B ;
Willke, A ;
Findik, D ;
Tuncer, I ;
Baysal, B ;
Günseren, F ;
Mamikoglu, L .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (05) :695-699
[2]
Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998 [J].
Babini, GS ;
Livermore, DM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (02) :183-189
[3]
Bush K, 2001, CLIN INFECT DIS, V32, P1085, DOI 10.1086/319610
[4]
Epidemiology and control of antibiotic resistance in the intensive care unit [J].
Carlet, J ;
Ben Ali, A ;
Chalfine, A .
CURRENT OPINION IN INFECTIOUS DISEASES, 2004, 17 (04) :309-316
[5]
Clonal diversity and antimicrobial susceptibility of Acinetobacter baumannii isolated in Spain.: A nationwide study:: GEIH-Ab project (2000) [J].
Fernández-Cuenca, F ;
Pascual, A ;
Ribera, A ;
Vila, J ;
Bou, G ;
Cisneros, JM ;
Rodríguez-Baño, J ;
Pachón, J ;
Marítinez-Martínez, L .
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2004, 22 (05) :267-271
[6]
Relationship between β-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii [J].
Fernández-Cuenca, F ;
Martínez-Martínez, L ;
Conejo, MC ;
Ayala, JA ;
Perea, EJ ;
Pascual, A .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (03) :565-574
[7]
Antibiotic resistance - from pathogen to disease surveillance [J].
Finch, R .
CLINICAL MICROBIOLOGY AND INFECTION, 2002, 8 (06) :317-320
[8]
Resistance surveillance in Italy: Four-year results from the MYSTIC program [J].
Fontana, R ;
Lo Cascio, G ;
Giacobone, E ;
Romero, E ;
Cipriani, P ;
Sessa, R ;
Franchino, L .
JOURNAL OF CHEMOTHERAPY, 2002, 14 (04) :323-331
[9]
Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units:: results from the European MYSTIC study group [J].
Goossens, H .
CLINICAL MICROBIOLOGY AND INFECTION, 2003, 9 (09) :980-983
[10]
Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries [J].
Hanberger, H ;
Garcia-Rodriguez, JA ;
Gobernado, M ;
Goossens, H ;
Nilsson, LE ;
Struelens, MJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (01) :67-71